Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139052 | 0.71 | MEN1 (0.45) | CYP2C9BLMPMP22CACNA1FCACNA1D | |
| SCHEMBL7890272 | 0.71 | CYP2C9 (0.39) | CYP2C9BLMPMP22CACNA1FCACNA1D | |
| SCHEMBL556387 | 0.71 | MAPT (0.36) | CYP2C9BLMPMP22CACNA1FCACNA1D | |
| SCHEMBL16865387 | 0.69 | LMNA (0.41) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL11453271 | 0.69 | CFTR (0.37) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA | |
| SCHEMBL5138601 | 0.68 | MEN1 (0.42) | CYP2C9MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL11470054 | 0.67 | CFTR (0.46) | CYP2C9BLMMAPTKCNH2LMNA | |
| SCHEMBL6979397 | 0.66 | CFTR (0.44) | CYP2C9BLMPMP22CACNA1FCACNA1D | |
| SCHEMBL10712315 | 0.66 | CYP2C9 (0.38) | CYP2C9BLMPMP22CACNA1FCACNA1D | |
| SCHEMBL11099941 | 0.64 | S100A4 (0.46) | CYP2C9BLMMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200499-A1 | Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners | BAYER CROPSCIENCE AG (DE) | 2008-08-21 | — | — | US | disclosed |
| EP-1773126-A1 | SELECTIVE INSECTICIDES AND/OR ACARICIDES BASED ON SUBSTITUTED, CYCLIC DICARBONYL COMPOUNDS AND SAFENERS | Bayer CropScience Aktiengesellschaft (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008107-A1 | SELECTIVE INSECTICIDES AND/OR ACARICIDES BASED ON SUBSTITUTED, CYCLIC DICARBONYL COMPOUNDS AND SAFENERS | BAYER CROPSCIENCE AG (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-6180568-B1 | HERBICIDES, MITICIDES, INSECTICIDES | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2001-01-30 | — | — | US | disclosed |
| EP-1026159-A1 | 4-ARYL-4-SUBSTITUTED PYRAZOLIDINE-3,5-DIONE DERIVATIVES | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200499-A1 | Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners | DDT, AADAC, ACMSD | CYP2C9 385/4885BLM 1695/4885PMP22 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.